Trial reports non-inferior seizure control with nighttime levetiracetam in a childhood epilepsy syndrome
Alternative dosing schedules had higher adherence and satisfaction, while seizure control and brain-recording results were reported as non-inferior to evenly split dosing.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For children with this specific epilepsy syndrome, nighttime-only and evening-weighted levetiracetam schedules were reported as non-inferior for seizure control and normalization of brain electrical recordings compared with evenly split dosing. Satisfaction and adherence were higher with the alternative schedules. The abstract does not provide enough detail to judge the allowed difference in seizure outcomes.
The trial was open-label. The abstract omits non-inferiority margins, outcome rates and confidence intervals, limiting assessment of how much difference was allowed and how precisely results were estimated.
What researchers found
Seizure control and electroencephalogram normalization
At 6 and 12 months, nighttime-only and evening-weighted schedules were reported as non-inferior to equal twice-daily doses; the abstract omits margins and confidence intervals.
What non-inferiority means
The study asked whether alternative schedules were not unacceptably worse than the evenly split schedule. A reported non-inferiority result does not mean the regimens were identical, or that nighttime dosing controlled seizures better.
Adherence and other outcomes
The alternative schedules had higher reported adherence and satisfaction. The nighttime-only group also had lower parent-rated scores for selected behavioral problems. No difference in adverse events was reported, which does not establish identical safety.
The original publication
Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial.
Fan L, Shen Y, Zhang J et al.
Sci Rep · 2025
- PubMed ID
- 41034293
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.